Adherium (ADR.ASX) is an ASX-listed digital health company developing technologies that address suboptimal medication use and remote patient management in chronic diseases. Adherium’s market-leading Smartinhaler platform has been independently proven to improve adherence to inhaled medications and improve health outcomes in chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). With an existing 10-year commercial product development and supply agreement with AstraZeneca (AZN) and strong relationships with other global pharmaceutical and medical technology companies and key opinion leaders (KOLs) through sales into the clinical trial sector, Adherium is positioned for strong revenue growth. The company listed on the ASX in August 2015, raising A$35m at A$0.50/share, including a US$3m investment by AZN.
In this interview, CEO Garth Sutherland provides an introduction to Adherium and the Smartinhaler technology platform. He discusses the strategic importance of the global supply agreement with AstraZeneca and highlights some key milestones to look out for over the next 12-24 months.
Posting Permissions
Reply With Quote
Социальные закладки